New hope for AML patients: targeted maintenance therapy after initial treatment

NCT ID NCT07304011

Recruiting now Disease control Sponsor: University of California, Davis Source: ClinicalTrials.gov ↗

First seen Jan 05, 2026 · Last updated May 29, 2026 · Updated 27 times

Summary

This study tests a two-step approach for adults with a specific type of acute myeloid leukemia (IDH1-mutated AML) who have already responded to initial therapy. First, patients receive a combination of two drugs (olutasidenib and azacitidine) to target cancer cells. Then, they continue on a maintenance drug (olutasidenib) to help prevent the cancer from coming back. The goal is to see if this strategy improves long-term outcomes after standard treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

University of California Davis Comprehensive Cancer Center
RECRUITING

Sacramento, California, 95817, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

ACUTE MYELOID LEUKEMIA